Russia’s Sputnik V Vaccine to Be Cheaper Than Rivals, Says Fund Head

MOSCOW (Reuters) -
A laboratory assistant holds a tube with Russia’s “Sputnik-V” vaccine against the coronavirus disease COVID-19. (Reuters)

Russia will charge less for its Sputnik V COVID-19 vaccine than rivals as Moscow aims to produce more than one billion doses at home and abroad next year, the head of Russia’s sovereign wealth fund said on Tuesday.

Details of the exact pricing are expected later on Tuesday, but Kirill Dmitriev, head of Russia’s RDIF sovereign wealth fund, told Reuters that Sputnik V would be priced significantly lower than other rivals with similar efficacy levels.

He was speaking after RDIF and the Gamaleya National Center said new clinical trial data based on 39 confirmed cases and 18,794 patients who got both shots had shown that Sputnik V was 91.4% effective on day 28 and over 95% effective on day 42.